Literature DB >> 7065830

Heterogeneity of psychiatric diagnosis in treated opiate addicts.

B J Rounsaville, M M Weissman, H Kleber, C Wilber.   

Abstract

A survey evaluated current and lifetime rates of psychiatric disorders in 533 opiate addicts in treatment at a multimodality program. Information was gathered using a structured interview format, the Schedule for Affective Disorders and Schizophrenia-Lifetime version, and the criteria were the Research Diagnostic Criteria. Most were give the diagnosis of at least one psychiatric disorder in addition to opiate addiction. The most common diagnoses were major depressive disorder, alcoholism, and antisocial personality, and rates of chronic minor mood disorders and anxiety disorders also were found to be elevated in comparison with those found in a community population. In contrast, rates of schizophrenia and mania were very low and did not exceed those reported for the general population. The findings are interpreted as suggesting the importance of detecting and attending to psychopathology associated with opiate addiction.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7065830     DOI: 10.1001/archpsyc.1982.04290020027006

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  41 in total

1.  Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.

Authors:  Jonathan D Savant; Declan T Barry; Christopher J Cutter; Michelle T Joy; An Dinh; Richard S Schottenfeld; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2012-07-06       Impact factor: 4.492

2.  Psychiatric diagnoses in a sample of HIV-infected people of color in methadone treatment.

Authors:  Mark G Winiarski; Lori I Greene; Alec L Miller; Nancy B Palmer; Jesus Salcedo; Maite Villanueva
Journal:  Community Ment Health J       Date:  2005-08

3.  A study of comorbidity in psychoactive substance dependence patients.

Authors:  P Kisore; N Lal; J K Trivedi; P K Dalal; V M Aga
Journal:  Indian J Psychiatry       Date:  1994-07       Impact factor: 1.759

4.  The mental status of 1090 heroin addicts at entry into treatment: should depression be considered a 'dual diagnosis'?

Authors:  Icro Maremmani; Matteo Pacini; Pier Paolo Pani; Giulio Perugi; Joseph Deltito; Hagop Akiskal
Journal:  Ann Gen Psychiatry       Date:  2007-11-13       Impact factor: 3.455

5.  Gender and comorbidity among individuals with opioid use disorders in the NESARC study.

Authors:  Christine E Grella; Mitchell P Karno; Umme S Warda; Noosha Niv; Alison A Moore
Journal:  Addict Behav       Date:  2009-01-30       Impact factor: 3.913

6.  Chronic neuroleptic treatment and mesolimbic dopamine denervation induce behavioural supersensitivity to opiates.

Authors:  L Stinus; M Winnock; A E Kelley
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  DOUBLE TROUBLE IN RECOVERY: SELF-HELP FOR PEOPLE WITH DUAL DIAGNOSES.

Authors:  Howard S Vogel; Edward Knight; Alexandre B Laudet; Stephen Magura
Journal:  Psychiatr Rehabil J       Date:  1998-03

8.  Drug abuse treatment success among needle exchange participants.

Authors:  R Brooner; M Kidorf; V King; P Beilenson; D Svikis; D Vlahov
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

9.  Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations.

Authors:  Peggy E Millson; Laurel Challacombe; Paul J Villeneuve; Benedikt Fischer; Carol J Strike; Ted Myers; Ron Shore; Shaun Hopkins; Sara Raftis; Mary Pearson
Journal:  Can J Public Health       Date:  2004 Mar-Apr

10.  Further evidence of an association between adolescent bipolar disorder with smoking and substance use disorders: a controlled study.

Authors:  Timothy E Wilens; Joseph Biederman; Joel J Adamson; Aude Henin; Stephanie Sgambati; Martin Gignac; Robert Sawtelle; Alison Santry; Michael C Monuteaux
Journal:  Drug Alcohol Depend       Date:  2008-03-17       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.